PhoreMost introduces GlueSEEKER platform for discovery of molecular glue degraders

PhoreMost Ltd., a leading UK biopharmaceutical company unlocking the next generation of drug targets, today announced the introduction of GlueSEEKER™. The new phenotypic screening platform expands the Company’s capabilities in this emerging therapeutic modality to support the systematic discovery and development of novel molecular glue degraders (MGDs) for targeted protein degradation (TPD).

MGDs are an important new class of small molecule drug that exhibit a therapeutic effect by enhancing the affinity between proteins, inducing new interactions or stabilizing a molecular complex. Similar to bivalent degraders like PROTACs, MGDs induce close proximity between target and effector proteins and are able to exploit the cell’s proteostasis mechanisms to cause target degradation. This approach has great potential in the treatment of diseases from cancer to neurodegeneration and beyond.

PhoreMost has developed the GlueSEEKER platform to overcome the challenges in discovering this class of molecule and provide a systematic discovery approach to address undruggable or otherwise unaddressed therapeutic targets. Expanding on the Company’s established SITESEEKER® degrader discovery platform, GlueSEEKER uses computationally designed intramolecular libraries to create a vast diversity of surface-edited E3 ligases. Phenotypic screening is then deployed to identify specific sites and precise changes resulting in induced degradation activity, integrating deep computational approaches with novel biological discovery.

The new GlueSEEKER platform has broad-ranging applications and is able to identify induced degradation events for almost any nominated neosubstrate and ligase pair, expanding the scope for this important modality and providing the Company and its partners with opportunities for novel therapeutic pipeline development. The technology innovation expands the Company’s activities in TPD and complements a growing internal pipeline of novel ligase-based bivalent degraders as they progress to development candidates.

GlueSEEKER builds on our expertise in the TPD space, offering an innovative solution to the rational discovery of new MGDs and for molecular glues beyond the degradation modality. This unique and powerful approach is a substantial augmentation of our existing platform technologies, providing new opportunities to unlock MGDs to help us and our partners to bring new precision medicines to fruition faster.”

Dr Benedict Cross, Chief Technology Officer, PhoreMost

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    PhoreMost. (2024, May 22). PhoreMost introduces GlueSEEKER platform for discovery of molecular glue degraders. News-Medical. Retrieved on June 15, 2024 from https://www.news-medical.net/news/20240522/PhoreMost-introduces-GlueSEEKER-platform-for-discovery-of-molecular-glue-degraders.aspx.

  • MLA

    PhoreMost. "PhoreMost introduces GlueSEEKER platform for discovery of molecular glue degraders". News-Medical. 15 June 2024. <https://www.news-medical.net/news/20240522/PhoreMost-introduces-GlueSEEKER-platform-for-discovery-of-molecular-glue-degraders.aspx>.

  • Chicago

    PhoreMost. "PhoreMost introduces GlueSEEKER platform for discovery of molecular glue degraders". News-Medical. https://www.news-medical.net/news/20240522/PhoreMost-introduces-GlueSEEKER-platform-for-discovery-of-molecular-glue-degraders.aspx. (accessed June 15, 2024).

  • Harvard

    PhoreMost. 2024. PhoreMost introduces GlueSEEKER platform for discovery of molecular glue degraders. News-Medical, viewed 15 June 2024, https://www.news-medical.net/news/20240522/PhoreMost-introduces-GlueSEEKER-platform-for-discovery-of-molecular-glue-degraders.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
PhoreMost and ThinkCyte collaborate to advance AI based drug discovery